Find information on neovascular glaucoma diagnosis, including clinical documentation, medical coding, and healthcare resources. Learn about relevant ICD-10 codes, treatment options, and differential diagnosis for neovascular glaucoma. Explore resources for healthcare professionals related to rubeosis iridis, angle closure glaucoma, and secondary glaucoma associated with neovascularization. Understand the role of medical coding accuracy in neovascular glaucoma management for optimal reimbursement and patient care. This resource provides valuable insights for ophthalmologists, optometrists, and other healthcare providers involved in the diagnosis and treatment of neovascular glaucoma.
Also known as
Glaucoma
Covers various types of glaucoma, including neovascular.
Background retinopathy
Often associated with neovascular glaucoma development.
Diabetes mellitus
A common underlying cause of neovascular glaucoma.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Neovascular Glaucoma due to diabetes?
When to use each related code
| Description |
|---|
| Neovascular glaucoma |
| Angle closure glaucoma |
| Open angle glaucoma |
Coding neovascular glaucoma without specifying laterality (right, left, bilateral) leads to claim rejections and inaccurate data.
Failure to code the underlying condition causing neovascular glaucoma (e.g., diabetes) impacts risk adjustment and quality reporting.
Missing documentation of glaucoma stage (e.g., early, advanced) affects severity coding and reimbursement accuracy.
Q: What are the key differentiating features in diagnosing neovascular glaucoma versus other forms of glaucoma like open-angle or angle-closure glaucoma?
A: Neovascular glaucoma (NVG) differs significantly from open-angle and angle-closure glaucoma in its underlying pathophysiology and clinical presentation. Unlike primary open-angle glaucoma (POAG) where the trabecular meshwork is progressively dysfunctional, or angle-closure glaucoma (ACG) where the iris blocks the trabecular meshwork, NVG arises from neovascularization of the iris and angle. This neovascularization is typically driven by ischemia from conditions like diabetic retinopathy, central retinal vein occlusion (CRVO), or carotid artery obstructive disease. Clinically, NVG often presents with more rapid and severe vision loss, elevated intraocular pressure (IOP), and characteristic gonioscopic findings like neovascularization of the angle (NVA). Explore how different diagnostic tools, including gonioscopy, can aid in differentiating NVG from other glaucoma types.
Q: How do I manage refractory neovascular glaucoma effectively when standard IOP-lowering medications are insufficient?
A: Managing refractory neovascular glaucoma, especially when topical and systemic IOP-lowering medications prove inadequate, requires a multi-pronged approach. First, address the underlying ischemic condition driving neovascularization. Panretinal photocoagulation (PRP) is often necessary to reduce the ischemic drive. If PRP is insufficient, consider anti-VEGF injections intravitreally which can regress neovascularization. For aggressive IOP control, surgical interventions such as glaucoma drainage devices or cyclodestructive procedures may be necessary. Consider implementing a stepped approach to treatment, starting with less invasive options and escalating as needed based on IOP response and disease progression. Learn more about the latest research on combination therapies for refractory NVG.
Patient presents with signs and symptoms consistent with neovascular glaucoma (NVG). The patient reports blurred vision, eye pain, and headaches. Ocular examination reveals elevated intraocular pressure (IOP), rubeosis iridis, neovascularization of the iris and or angle (NVA), and in some cases, open or closed anterior chamber angle. Gonioscopy confirms the presence of neovascularization in the angle. The underlying cause of NVG is suspected to be [Specify underlying condition e.g., proliferative diabetic retinopathy, central retinal vein occlusion, carotid artery obstructive disease, etc.]. Visual acuity is [Document visual acuity e.g., 2040 OD, 2020 OS]. The patient's medical history includes [List relevant medical history, including diabetes, hypertension, cardiovascular disease]. Current medications include [List current medications]. Assessment: Neovascular glaucoma secondary to [Underlying cause]. Plan: The treatment plan aims to lower IOP and address the underlying cause. Options include topical IOP-lowering medications such as aqueous suppressants (beta-blockers, alpha-agonists, carbonic anhydrase inhibitors) and prostaglandin analogs. Consideration for panretinal photocoagulation (PRP) is warranted to reduce ischemic drive for neovascularization. Anti-VEGF therapy may be considered. The patient will be closely monitored for IOP control and progression of neovascularization. Follow-up appointment scheduled in [Duration] to reassess treatment efficacy and consider further intervention if necessary. Differential diagnoses included other secondary glaucomas such as angle closure glaucoma and inflammatory glaucoma, but the clinical picture is most consistent with NVG given the presence of NVA. ICD-10 code H40.153 (Neovascular glaucoma, unspecified eye, with pain) or H40.154 (Neovascular glaucoma, unspecified eye, without pain) may be applicable depending on the presence of pain. CPT codes for services rendered will be documented separately.